--- canonical_name: Chaste Tree alternate_names: Vitex agnus-castus, Vitex, Chasteberry, Chaste Berry, Monk's Pepper, Agnus Castus, Abraham's Balm canonical_topic: Chaste Tree for Health & Longevity short_topic_lc: chaste_tree creation_date: 2026-0825-1111 creator_ai_fullname: Opus 5 ep_keywords: Dopamine Agonists, Prolactin Inhibitors, Hormones --- # Chaste Tree for Health & Longevity
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** *Vitex agnus-castus*, Vitex, Chasteberry, Chaste Berry, Monk's Pepper, Agnus Castus, Abraham's Balm ## Motivation Chaste tree is a Mediterranean shrub whose small, peppercorn-like dried fruit has been used as a medicine for more than two thousand years. Modern extracts of the fruit act on the hormone-control center at the base of the brain, where they dampen release of the milk-producing hormone prolactin. Because that hormone also shapes the monthly cycle, the plant has become a mainstay of women's herbal medicine. European physicians have prescribed standardized chaste tree preparations since the middle of the last century, and it remains one of the few plant medicines licensed as a regulated medicine in Germany for cycle-related complaints. Premenstrual symptoms, tender breasts, and irregular cycles are common enough that many adults look for an option that is neither hormonal contraception nor an antidepressant. This review examines what the clinical evidence shows about chaste tree: how it is thought to work, which effects hold up and which do not, the risks and interactions that follow from its hormonal action, how it is dosed and monitored, and how sound the underlying research is. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews of chaste tree from clinicians, expert platforms, and narrative reviews that discuss the plant itself rather than pooling trial data. * [Premenstrual Syndrome Overview](https://www.lifeextension.com/protocols/female-reproductive/premenstrual-syndrome) - Life Extension Devotes a dedicated section to chaste tree, walking through the placebo-controlled dose-ranging trials and setting the herb directly against conventional antidepressant and hormonal options for the same indication. * [The Dos and Don'ts of Vitex for Period Problems](https://www.larabriden.com/vitex-for-period-problems/) - Lara Briden A practicing clinician's operating rules for chaste tree: morning dosing, follicular-phase timing, monthly breaks, and explicit warnings against combining it with fertility medication or starting it immediately after oral contraceptives. * [Chaste tree (Vitex agnus-castus) — pharmacology and clinical indications](https://pubmed.ncbi.nlm.nih.gov/12809367/) - Wuttke et al., 2003 The Göttingen group's own account of isolating the dopamine-like diterpenes and tying them to prolactin suppression. Still the clearest statement of the mechanism the whole field rests on. * [Vitex agnus castus effects on hyperprolactinaemia](https://pubmed.ncbi.nlm.nih.gov/38075075/) - Puglia et al., 2023 Endocrinologists assess whether the herb can substitute for prescription dopamine-mimicking drugs in mild prolactin excess, and are candid that the case rests on small series rather than controlled trials. * [Effects, Mechanisms of Action and Application of Vitex agnus-castus for Improvement of Health and Female Reproduction](https://pubmed.ncbi.nlm.nih.gov/39853839/) - Sirotkin, 2025 A recent narrative synthesis mapping the plant's constituents onto ovarian, pituitary and intracellular targets. The broadest current survey of indications beyond premenstrual syndrome. Note on the priority experts: of the six priority platforms, only Life Extension carries content that examines chaste tree in depth. Site searches of foundmyfitness.com, peterattiamd.com, hubermanlab.com and lifespan.io returned no chaste tree content whatsoever. chriskresser.com mentions the herb in a single sentence inside a broader article on menstrual cycle repair, which is too thin to qualify as a high-level overview, so it was not listed. Five qualifying items were found and listed. ## Grokipedia * [Vitex agnus-castus](https://grokipedia.com/page/Vitex_agnus-castus) Covers the plant's botany, phytochemistry, traditional use and clinical evidence in one place, and traces the libido-suppressing reputation to the plant's Greek name and its medieval monastic use. ## Examine * [Chaste Tree](https://examine.com/supplements/chaste-tree/) Grades the outcomes separately, assigning its highest confidence to premenstrual symptoms and a lower grade to irritability, and gives concrete dose equivalences for the two standardized extracts used in trials. ## ConsumerLab ConsumerLab has no dedicated chaste tree article, product review or testing report. The herb appears only inside a broader premenstrual syndrome question-and-answer entry, and no chaste tree products have been through the site's independent testing program. ## Systematic Reviews The pooled evidence base for chaste tree, covering both the claimed benefits and the safety record. * [The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/28237870/) - Verkaik et al., 2017 Pooled fourteen randomized trials. Large effect on total premenstrual symptoms, which the authors judge inflated by bias, heterogeneity and selective publication. * [Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials](https://pubmed.ncbi.nlm.nih.gov/31780016/) - Csupor et al., 2019 Restricted to three properly characterized extract trials. The surviving evidence still favors chaste tree, at roughly two and a half times the placebo remission rate. * [Vitex Agnus-Castus for the Treatment of Cyclic Mastalgia: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/31464546/) - Ooi et al., 2020 Twenty-five trials on cyclical breast pain. A conservative six-trial pooled analysis shows moderate benefit over placebo and non-inferiority to several prescription comparators. * [Vitex agnus castus: a systematic review of adverse events](https://pubmed.ncbi.nlm.nih.gov/15783241/) - Daniele et al., 2005 The only systematic safety review. Pooling trials, surveillance and regulator reports, it finds adverse events mild, reversible, and dominated by nausea, headache and rash. * [The effects of Vitex agnus-castus on menstrual bleeding: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/31369395/) - Mollazadeh et al., 2019 A negative result. Pooled trials show no effect on menstrual blood loss, and less benefit than a standard anti-inflammatory painkiller in the first cycle. ## Mechanism of Action Chaste tree fruit is a multi-constituent botanical extract rather than a single drug, and its best-characterized action is dopaminergic. Clerodane diterpenes — chiefly rotundifuran and viteagnusin I — and, more recently, triterpenes such as 3-epi-maslinic acid activate the dopamine D2 receptor (the receptor through which dopamine normally restrains hormone release) on the prolactin-secreting cells of the anterior pituitary, with half-maximal activity around 5–13 micromolar ([Reinhardt et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39519010/); co-authored by employees of Max Zeller Söhne, maker of one of the two trial-validated extracts, and most of the field's evidence carries a comparable commercial fingerprint). Dopamine is the body's natural brake on prolactin, so the net effect is reduced prolactin output, which eases breast tenderness and lengthens a shortened luteal phase (the second half of the cycle, after ovulation). Two further actions are documented. Extracts bind and activate mu- and delta-opioid receptors, which mediate endorphin signaling and are thought to be underactive premenstrually ([Webster et al., 2011](https://pubmed.ncbi.nlm.nih.gov/20854795/)). The flavonoid apigenin binds selectively to estrogen receptor beta, one of the two receptor types through which estrogen acts ([Jarry et al., 2003](https://pubmed.ncbi.nlm.nih.gov/14648399/)). The account is contested. The prolactin hypothesis predicts benefit mainly where prolactin is elevated, yet most trial participants had normal prolactin and symptom relief did not track prolactin change; critics attribute the effect instead to the opioid or estrogenic actions, or to the roughly 50% placebo response. Human pharmacokinetics are unmapped: no half-life, tissue distribution, metabolic pathway or drug-metabolizing enzyme has been established for the marker compounds agnuside and casticin. ## Historical Context & Evolution Chaste tree entered the written record in classical Greece. Dioscorides, Theophrastus and Pliny describe the fruit as an agent for calming sexual desire and for disorders of the womb, and Athenian women are reported to have strewn their beds with its branches during the Thesmophoria festival. The Latin epithet *agnus castus* and the folk name monk's pepper both preserve the anti-libidinal claim, on which medieval monastic communities relied. That original use has never been tested in a controlled study; it remains an inherited assertion rather than a finding. The plant's second life began in Germany in the 1930s and 1940s, when the first standardized tinctures were manufactured and the indication was reoriented from libido to the menstrual cycle. Clinical interest converged on latent hyperprolactinemia — a mild prolactin excess that surfaces only under stress or during deep sleep — as the driver of premenstrual breast pain, and a placebo-controlled trial in women with a shortened luteal phase reported normalized cycle length and restored progesterone ([Milewicz et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8369008/)). Germany's Commission E, the government expert committee that evaluates herbal medicines and derives no revenue from its conclusions, approved the herb in 1992 for cycle irregularities, premenstrual complaints and breast pain. International attention followed a placebo-controlled trial in a major general medical journal ([Schellenberg, 2001](https://pubmed.ncbi.nlm.nih.gov/11159568/)). Opinion has since moved in both directions: later pooling confirmed a signal but exposed publication bias, while the prolactin explanation itself came under question as evidence accumulated. Neither the enthusiastic nor the skeptical reading has settled. ## Expected Benefits ### High 🟩 🟩 🟩 #### Relief of Premenstrual Syndrome Symptoms Chaste tree extracts reduce the cluster of irritability, mood change, anger, headache, bloating and breast fullness that defines premenstrual syndrome (the recurring physical and mood symptoms in the days before a period). Two independent meta-analyses of randomized controlled trials — studies that assign participants by chance to treatment or placebo — both favor the herb. The larger warns that its effect is inflated by risk of bias, extreme between-trial heterogeneity and demonstrable publication bias; the stricter one, limited to well-characterized extracts, still finds a clear advantage. **Magnitude:** Responder rates, defined as at least a 50% fall in symptoms over three cycles, were 52% on active treatment versus 24% on placebo ([Schellenberg, 2001](https://pubmed.ncbi.nlm.nih.gov/11159568/)). Pooled across properly characterized extract trials in 520 women, remission was 2.57 times as likely (95% confidence interval — the range within which the true value probably lies — 1.52 to 4.35) ([Csupor et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31780016/)). #### Reduction of Cyclical Breast Pain Cyclical mastalgia — breast pain that recurs predictably in the second half of the cycle, with or without a full premenstrual picture — has the tightest mechanistic logic of any indication, being the symptom most closely tied to prolactin excess. A systematic review and meta-analysis found consistent reductions in pain intensity alongside falls in serum prolactin. Seven trials found the herb no worse than prescription comparators, including dopamine agonists (drugs that mimic dopamine, such as bromocriptine), anti-inflammatory painkillers and hormonal contraceptives. **Magnitude:** Standardized mean difference 0.67 (95% confidence interval 0.5 to 0.85) versus placebo across six trials in 718 women, a moderate effect ([Ooi et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31464546/)). In a dedicated trial, pain fell 34.3 mm on a 100 mm rating scale after three cycles versus 25.7 mm on placebo ([Halaska et al., 1999](https://pubmed.ncbi.nlm.nih.gov/14731436/)). ### Medium 🟩 🟩 #### Correction of Latent Hyperprolactinemia and Short Luteal Phase Latent hyperprolactinemia is a mild prolactin excess that appears only on provocation testing or during sleep, and it can shorten the luteal phase and blunt progesterone output. A small placebo-controlled trial in women with exactly this pattern reported normalized luteal length and restored progesterone after three months, with other hormones unchanged. Endocrinologists reviewing the wider literature judge the herb a plausible option in mild cases, but stress that the supporting material is small trials and case series rather than adequately powered studies. **Magnitude:** Seventeen treated women showed reduced provoked prolactin release, normalized luteal phase length and restored luteal progesterone, while twenty placebo recipients did not; the literature reports no outcome figure for the size of the prolactin fall ([Milewicz et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8369008/)). The direction is consistent across the review literature and holds only where prolactin is genuinely elevated ([Puglia et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38075075/)). ### Low 🟩 #### Relief of Menstrual Pain and Cycle Irregularity Real-world data in 1,700 women taking two licensed chaste tree products for three months recorded large improvements in menstrual pain and bleeding regularity. The design was retrospective and uncontrolled, the manufacturer employed most authors, and a dedicated randomized trial in painful periods has completed without reporting. **Magnitude:** Menstrual pain improved in 85.2% and bleeding frequency in 79.2% of 1,700 women over three months, and irregular cycles fell from 9.1% to 0.1% ([Höller et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38393671/)). Uncontrolled, so the placebo share of these figures is unknown. #### Improvement of Metabolic and Oxidative Markers in Polycystic Ovary Syndrome A 12-week randomized trial in 60 women with polycystic ovary syndrome (a common hormonal disorder marked by irregular cycles, excess male-type hormones and multiple ovarian follicles) reported improved antioxidant capacity, insulin sensitivity and hirsutism (excess body and facial hair). Single-center, small, and not yet replicated. **Magnitude:** Versus placebo over 12 weeks, the insulin resistance index fell 0.31, the modified Ferriman–Gallwey hirsutism score fell 5.38 points, high-density lipoprotein rose, and menstrual frequency increased ([Hatami et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41428718/)). ### Speculative 🟨 #### Relief of Perimenopausal Symptoms ⚠️ Conflicted Uncontrolled series suggest benefit for hot flashes and mood in late perimenopause. The one adequately powered randomized trial of a chaste tree combination found no advantage over placebo ([van Die et al., 2009](https://pubmed.ncbi.nlm.nih.gov/18791483/)). #### Support of Fertility in Luteal Phase Deficiency Two pregnancies occurred in the small luteal-phase trial, and herbalists use the plant for progesterone-related subfertility. No controlled trial has used pregnancy or live birth as an endpoint, so the basis is mechanistic and anecdotal. #### Improvement of Sexual Function ⚠️ Conflicted A 16-week randomized trial in 102 women found a higher overall sexual function score than placebo, though no individual domain reached significance ([Heirati et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34667794/)). That contradicts the plant's ancient libido-suppressing reputation. ## Benefit-Modifying Factors * **DRD2 and ANKK1 variants:** DRD2 codes for the dopamine D2 receptor, and the neighboring ANKK1 Taq1A variant reduces receptor density. Carriers may need more dopaminergic stimulus for the same prolactin suppression, though no chaste tree trial has genotyped participants. * **Baseline prolactin:** Benefit tracks most closely with an elevated or provocable prolactin level. Women with normal prolactin still improved in trials, but the mechanistic rationale is weaker and the response is likelier to reflect opioid or placebo pathways. * **Baseline progesterone and luteal length:** A mid-luteal progesterone below the ovulatory threshold, or a luteal phase shorter than eleven days, marks the subgroup in which cycle-normalizing effects were actually demonstrated. Adequate luteal function leaves less room to improve. * **Sex-based differences:** Essentially all clinical evidence comes from women of reproductive age. In men only animal work exists, showing dose-dependent changes in luteinizing hormone and testosterone. Human benefit in men is undocumented at any dose. * **Pre-existing health conditions:** Polycystic ovary syndrome responses are inconsistent and occasionally worse. Loss of periods driven by energy deficit does not respond until intake is restored. Prolactin-secreting pituitary tumors require specialist management rather than herbal substitution. * **Age-related considerations:** Effects depend on an intact cycle. Under 18 the hypothalamic-pituitary-ovarian axis (the brain-ovary signaling loop that drives the cycle) is still maturing, and benefit fades through late perimenopause and disappears after the final period. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Gastrointestinal Upset and Nausea The most frequently reported adverse effect across controlled trials, post-marketing surveillance and manufacturer records. It is mild, appears early, and resolves on stopping or when the dose is taken with food. No mechanism is established; direct mucosal irritation by the fruit's essential oils is the usual assumption. It does not escalate with continued use, and in controlled trials the overall adverse-event rate did not exceed placebo. **Magnitude:** Nausea and gastrointestinal disturbance head the adverse-event list in the only systematic safety review, which reports no pooled incidence figure ([Daniele et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15783241/)). In the largest placebo-controlled trial, 4 of 86 women on active treatment reported any adverse event versus 3 of 84 on placebo, and none discontinued ([Schellenberg, 2001](https://pubmed.ncbi.nlm.nih.gov/11159568/)). #### Headache and Fatigue Headache and non-specific fatigue rank alongside nausea as leading complaints in the pooled safety literature and in professional drug references. Dopamine-active drugs commonly provoke both, so a receptor-mediated effect is plausible. Neither has been separated from the premenstrual headache and fatigue the herb is taken to treat, which makes attribution uncertain. Both are mild and fully reversible on discontinuation. **Magnitude:** Headache and fatigue are listed among the most frequent events without an incidence rate; the literature reports no outcome figure for either. Overall adverse-event rates did not exceed placebo in the controlled trials pooled ([Daniele et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15783241/)). ### Medium 🟥 🟥 #### Menstrual Cycle Disturbance and Intermenstrual Bleeding Changes in cycle length, spotting between periods and altered bleeding timing appear in every safety summary. This follows directly from the mechanism, since shifting prolactin alters when ovulation occurs. It is the adverse effect most likely to prompt discontinuation, and it reverses within one to two cycles of stopping. Anyone tracking cycle data will detect it before it becomes disruptive. **Magnitude:** Menstrual disorders are among the most frequently reported events, with no pooled incidence figure given ([Daniele et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15783241/)). Pooled trials found no change in measured menstrual blood loss versus placebo, so the disturbance is one of timing rather than volume ([Mollazadeh et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31369395/)). #### Acne ⚠️ Conflicted Acne appears consistently in adverse-event listings, which is notable because the same herb is used clinically to treat hormonally driven acne. The likely explanation is bidirectional: shifting prolactin and the estrogen-to-progesterone balance can improve or worsen sebum production depending on the starting hormonal pattern. Direction is therefore individual and cannot be predicted from baseline testing. **Magnitude:** Acne is listed among the most frequent adverse events, with no incidence rate reported in the pooled safety literature ([Daniele et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15783241/)). The direction depends on baseline hormonal pattern and is not quantified in either direction. ### Low 🟥 #### Hypersensitivity Skin Reactions Pruritus (itching), urticaria (raised itchy welts) and erythematous rash (a red inflamed rash) are documented in trial and post-marketing data. These are allergic rather than hormonal, appear early, and require discontinuation rather than dose reduction. **Magnitude:** Pruritus and erythematous rash appear on the frequent-event list with no incidence figure reported, and no serious or irreversible hypersensitivity reaction has been recorded ([Daniele et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15783241/)). #### Masking of an Underlying Prolactin-Secreting Pituitary Tumor Because the herb lowers prolactin and restores menstruation, it can normalize the two signals that would otherwise prompt investigation of a prolactinoma. A published case describes exactly this delay in diagnosis. **Magnitude:** Not quantified in available studies. Only a single case report exists, and no cohort has measured how often a pituitary tumor is missed this way ([Gallagher et al., 2008](https://pubmed.ncbi.nlm.nih.gov/17298863/)). #### Multiple Follicular Development With Concurrent Fertility Treatment A woman undergoing assisted reproduction who added a chaste tree preparation developed disordered gonadotropin and ovarian hormone levels and mild ovarian hyperstimulation syndrome (painful ovarian swelling and fluid shift). The disturbance resolved once the herb was stopped. **Magnitude:** Not quantified in available studies. Only a single case report exists, and no cohort or trial has measured how often the interaction occurs ([Cahill et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7989506/)). ### Speculative 🟨 #### Loss of Effect From Dopamine-Blocking Medication Antipsychotics and metoclopramide block the same receptor chaste tree activates, so mutual interference is expected. No clinical case of either reduced antipsychotic effect or lost herbal effect has been published; the concern is purely mechanistic. #### Stimulation of Hormone-Sensitive Tissue Apigenin in the extract activates estrogen receptor beta, and manufacturers and reference sources caution against use in estrogen-sensitive cancers. No human data link chaste tree to tumor growth; the caution rests on receptor binding alone. ## Risk-Modifying Factors * **DRD2 and ANKK1 variants:** Reduced dopamine D2 receptor density may blunt both the intended prolactin suppression and the dopamine-related side effects such as headache. No chaste tree study has genotyped participants, so this remains an inference from receptor pharmacology. * **Baseline prolactin:** A prolactin already at the low end of range leaves less headroom before suppression disturbs ovulation timing, making cycle irregularity and spotting likelier. A high baseline needs its cause identified before any herbal treatment begins. * **Baseline thyroid and liver markers:** An underactive thyroid itself raises prolactin, so treating the resulting symptoms with chaste tree can mask it. No liver toxicity signal exists, but baseline liver enzymes give a reference point if symptoms appear later. * **Sex-based differences:** All safety data derive from women. In men, the endocrine consequences of sustained prolactin suppression are unstudied and the traditional libido-suppressing claim has never been tested, so the risk profile is simply unknown. * **Pre-existing health conditions:** Estrogen-sensitive breast, uterine and ovarian cancers, prolactin-secreting pituitary tumors, and pregnancy shift the risk sharply. Concurrent assisted reproduction adds the follicular-development risk. Antipsychotic treatment raises interaction concern. * **Age-related considerations:** Under 18 the brain-ovary signaling loop is still maturing and disturbance is a theoretical concern. Beyond the final period the herb offers no cycle benefit while retaining its hypersensitivity and interaction risks. ## Key Interactions & Contraindications * **Dopamine-blocking prescription drugs (antipsychotics such as haloperidol, risperidone, amisulpride; the anti-nausea drug metoclopramide):** Caution. Mutual pharmacological opposition may reduce the herb's prolactin-lowering effect and, in theory, psychiatric control. Prefer separate use; if combined, monitor psychiatric stability and prolactin. * **Dopamine agonists (bromocriptine, cabergoline):** Caution. Additive prolactin suppression can drive levels below normal and disrupt the cycle. Chaste tree has been compared with, not added to, these drugs. If both are used, monitor prolactin and reduce the agonist dose under supervision. * **Ovulation-induction and assisted reproduction drugs (clomiphene, letrozole, injectable gonadotropins):** Absolute contraindication during a treatment cycle. Disordered follicular development and mild ovarian hyperstimulation have been reported. Stop chaste tree before stimulation begins and do not resume until the cycle concludes. * **Combined oral contraceptives and menopausal hormone therapy:** Caution. Theoretical opposition, since chaste tree acts on the pituitary-ovarian signaling these suppress. No pharmacokinetic interaction is documented. Watch for breakthrough bleeding, and do not assume the herb alters contraceptive reliability in either direction. * **Over-the-counter agents (cimetidine where sold without prescription; sedating antihistamines with dopamine-blocking activity, such as promethazine):** Caution. Both raise prolactin and directly oppose the herb's mechanism, blunting benefit. Prefer famotidine or a non-sedating antihistamine when a stomach-acid or allergy medicine is needed alongside. * **Supplements with additive dopaminergic or prolactin-lowering effect (*Mucuna pruriens*, which supplies L-DOPA; high-dose vitamin B6, also called pyridoxine; zinc):** Caution. Stacking these can over-suppress prolactin and disturb cycle timing. Vitamin B6 above 100 mg daily long-term also carries its own nerve-damage risk. * **St. John's wort (*Hypericum perforatum*), commonly co-formulated with chaste tree:** Caution. It induces CYP3A4, the liver's main drug-clearing enzyme, and lowers levels of many prescription drugs including oral contraceptives. Such combination products carry St. John's wort's interaction profile, not chaste tree's. * **Other interventions:** Caution. Dopamine-active recreational and cognition-enhancing compounds, and prolactin-raising opioid analgesics, act on the same axis. Effects are additive or opposing depending on direction, and none has been quantified in humans. **Populations who should avoid Chaste tree:** * Pregnancy at any stage — theoretical uterine-stimulant, estrogenic and progestogenic activity, with no human safety data * Breastfeeding — prolactin suppression may reduce milk supply, and transfer into milk has not been characterized * Estrogen-sensitive cancers — breast, endometrial or ovarian, whether active or in remission * Prolactin-secreting pituitary tumor larger than 10 mm, or any tumor requiring drug therapy * Anyone within an active ovulation-induction or in vitro fertilization cycle, and for at least four weeks beforehand * Adolescents under 18 outside specialist supervision * Anyone taking an antipsychotic for which prolactin elevation forms part of therapeutic monitoring ## Risk Mitigation Strategies * **Hold to the trial-validated dose:** 20 mg daily of standardized extract beat 8 mg and matched 30 mg, so escalating past 20 mg adds adverse-event exposure without benefit. Prevents dose-driven nausea and headache. * **Take the dose with breakfast if nausea appears:** Gastrointestinal upset is the most common adverse effect and usually resolves when the morning dose follows food rather than being taken fasted. Prevents the leading cause of discontinuation. * **Run a defined three-cycle trial, then stop and reassess:** Benefit is fully expressed by the third cycle. A fixed endpoint prevents indefinite exposure to cycle disturbance and hypersensitivity risk in people who are not responding. * **Stop at least four weeks before any fertility treatment cycle:** Prevents the disordered follicular development and mild ovarian hyperstimulation reported when the herb was combined with in vitro fertilization stimulation. * **Investigate rather than treat a prolactin above 25 ng/mL:** A level above the reference range warrants thyroid testing, a medication review, and pituitary imaging if persistent. Prevents masking a prolactinoma or an untreated underactive thyroid. * **Discontinue immediately for rash, hives or itching:** These reactions are allergic rather than dose-related and do not adapt with continued use. Prevents progression of a hypersensitivity reaction. * **Log cycle length and spotting for the first two cycles:** Stopping at the first sustained change prevents prolonged cycle disruption, which otherwise reverses within one to two cycles once the herb is withdrawn. * **Confirm the label names a standardized extract:** Verify Ze 440, BNO 1095, or a stated agnuside content. Prevents underdosing with unquantified whole-fruit powder, the commonest reason a trial of the herb fails to show anything. ## Therapeutic Protocol * **Standard European protocol:** 20 mg daily of the standardized dry fruit extract Ze 440, or 4 mg of the 10:1 extract BNO 1095 (equivalent to 40 mg dried fruit), taken continuously for at least three menstrual cycles. * **Anglo-American herbalist protocol:** A 1:2 liquid fruit extract at 1–4 mL daily, or 150–250 mg of dried fruit, as taught by the Australian phytotherapy school around Kerry Bone. No head-to-head comparison against standardized tablets exists. * **Combination protocol:** German practice also uses Mastodynon, a chaste tree combination preparation, alongside the Agnucaston and Cyclodynon single-herb products. All three come from Bionorica, whose employees authored the main real-world evidence supporting them. * **Dose-finding basis:** A three-arm comparison established 20 mg as the optimum, significantly better than both 8 mg and placebo, with no further gain at 30 mg ([Schellenberg et al., 2012](https://pubmed.ncbi.nlm.nih.gov/23022391/)). * **Best time of day:** Morning, ideally on rising. Prolactin output peaks during sleep and early morning, so morning dosing places the dopaminergic effect where the target signal is highest. * **Half-life and dosing frequency:** No human half-life has been published for the extract or for its markers agnuside and casticin. Every pivotal trial used once-daily dosing, which is therefore the only regimen with supporting evidence. * **Single versus split dosing:** A single morning dose. Splitting has never been trialed and would dilute the morning effect on which the timing rationale depends. * **Genetic polymorphisms:** No pharmacogenetic guidance exists. DRD2 and ANKK1 Taq1A carriers may respond less, and the metabolism of the extract is uncharacterized, so genotype cannot currently inform dose selection. * **Sex-based differences:** Protocols are defined only for women of reproductive age. No dosing regimen for men has been trialed at any dose or for any duration, so no protocol can be stated. * **Age-related considerations:** The same dose applies across adult reproductive years. Avoid under 18 outside specialist care. After the final menstrual period there is no cycle to modify and the protocol does not apply. * **Baseline biomarkers:** Measure prolactin, mid-luteal progesterone and thyroid-stimulating hormone before starting. Normal prolactin does not preclude a trial, but it lowers the prior probability of a genuine drug response. * **Pre-existing health conditions:** Lower expectations in polycystic ovary syndrome, where response is inconsistent. Restore energy intake first where periods stopped from under-fueling, since the herb cannot override an energy deficit. ## Discontinuation & Cycling * **Intended duration:** Short to medium term rather than lifelong. Three to six months is the conventional course for cycle regulation. Continuous use for premenstrual mood symptoms is common in practice but untested beyond roughly six months. * **Withdrawal effects:** None documented. No dependence, rebound prolactin surge or discontinuation syndrome appears in the safety literature. Symptoms typically return over one to three cycles as the original hormonal pattern reasserts itself. * **Tapering protocol:** Not required. Every trial stopped abruptly at the end of the treatment period without adverse consequence, so an abrupt stop is the evidenced approach and a taper adds nothing. * **Cycling:** Practitioners commonly advise a five-day break during menstruation, or a six-month course followed by a break, arguing that continuous use attenuates the effect. No trial has compared cycling against continuous dosing. * **Reassessment after stopping:** Stop after three cycles and observe one unmedicated cycle. This separates a genuine drug effect from spontaneous improvement, which reached roughly 50% in the placebo arms of the major trials. ## Sourcing and Quality * **Extract identity outranks brand:** Only two extracts carry the pivotal trial evidence — Ze 440 from Max Zeller Söhne (sold as Prefemin and Premular) and BNO 1095 from Bionorica (sold as Agnucaston and Cyclodynon). Products naming neither have no direct efficacy data. * **Standardization markers:** Look for a stated agnuside content, typically around 0.6%, or casticin. These are analytical markers rather than the active diterpenes, so they certify identity and batch consistency rather than potency. * **Species adulteration:** Fruit of related species such as *Vitex trifolia* is a documented substitute in some markets, and chromatographic marker methods exist to distinguish them. A reputable supplier will confirm botanical species identity on request. * **Third-party testing:** Prefer products carrying USP Verified, NSF Contents Certified or an equivalent independent seal, or a supplier that publishes batch certificates of analysis covering identity, heavy metals, pesticide residues and microbial limits. * **Formulation:** Standardized dry extract tablets carry the trial evidence. Alcoholic tinctures are the traditional form and were used in the breast-pain solution trial. Loose dried fruit and teas deliver unquantified and unreliable doses. * **Reputable suppliers:** In Europe, Bionorica and Max Zeller Söhne market licensed medicinal products manufactured to pharmaceutical standards. In the United States, Nature's Way, Gaia Herbs and Vitanica are established suppliers, though none uses a trial-validated extract. ## Practical Considerations * **Time to effect:** Partial relief appears within the first cycle, and the full effect requires three. Trials stopping at one cycle systematically understate benefit. Cycle-regulating effects can take up to six months to stabilize. * **Common pitfalls:** Stopping after one cycle; taking it in the evening; buying unquantified whole-fruit powder; using it while on hormonal contraception, where there is no natural cycle to modify; and expecting it to override an energy deficit. * **Regulatory status:** In the United States it is a dietary supplement under the 1994 supplement act, so no efficacy review precedes sale. In Germany and much of the European Union it is a licensed herbal medicinal product with an approved indication. * **Cost and payer incentives:** Roughly 10–20 US dollars per month, comparable to generic antidepressants and oral contraceptives. Because no competing option is expensive, institutional payers have no systematic incentive favoring one, so cost is not distorting guideline formation here. * **Accessibility:** Sold without prescription in the United States, United Kingdom and Australia. In Germany the licensed products are pharmacy-only, which narrows access but guarantees pharmaceutical-grade manufacturing and batch documentation. ## Interaction with Foundational Habits * **Sleep:** Indirect and bidirectional. Prolactin surges during deep sleep, and that nocturnal surge is the presumed driver of latent prolactin excess, so fragmented sleep amplifies the very abnormality being treated. Chaste tree is not sedating and does not disturb sleep architecture. Correcting sleep first may reduce the target signal. * **Nutrition:** Direct and minor. No nutrient depletion is documented. Taking the morning dose with food reduces nausea, with no evidence of reduced absorption. Several trials paired the herb with vitamin B6 and magnesium; both appear additive for premenstrual symptoms rather than interfering with it. * **Exercise:** Indirect and conditional. Chaste tree neither blunts nor enhances training adaptation, and timing relative to workouts is irrelevant. High training volume with inadequate energy intake suppresses the cycle centrally, and the herb cannot override that; restoring energy intake takes precedence over any supplement. * **Stress management:** Direct and potentiating. Psychological stress triggers prolactin release, the same signal chaste tree suppresses, so the two act on one endpoint from opposite directions. Stress reduction is therefore additive, and unmanaged stress is a plausible explanation for non-response. ## Monitoring Protocol & Defining Success Baseline testing serves two purposes: it identifies the subgroup most likely to respond, and it rules out the conditions that a symptomatic response would otherwise mask. Before starting, measure prolactin in the early follicular phase, mid-luteal progesterone timed roughly seven days before the expected period, and thyroid-stimulating hormone. Where periods are irregular, add luteinizing hormone, follicle-stimulating hormone and estradiol. Liver enzymes and ferritin give reference points should symptoms or heavy bleeding arise later. Ongoing monitoring is light. Repeat prolactin and mid-luteal progesterone after three cycles, the point at which the treatment effect should be fully expressed, and again at six months if the herb is continued. Thereafter every six to twelve months is sufficient. Any new spotting, sustained shift in cycle length, or breast change warrants earlier retesting rather than waiting for the scheduled interval. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Prolactin | 5–15 ng/mL | Primary mechanistic target; identifies likely responders | Conventional laboratory range extends to roughly 25 ng/mL, so functional targets are tighter. Draw mid-morning, fasted, after 30 minutes seated rest. Stress, nipple stimulation and recent exercise all raise it; repeat any high value before acting | | Progesterone (mid-luteal) | Above 10 ng/mL | Confirms ovulation and adequate luteal function, the endpoint chaste tree is meant to restore | Conventional laboratories treat anything above 3 ng/mL as merely confirming ovulation, a much lower bar. Time to roughly 7 days before the expected period rather than a fixed calendar day | | Thyroid-stimulating hormone (TSH) | 0.5–2.0 mIU/L | An underactive thyroid raises prolactin and mimics the picture chaste tree is used for | TSH is the pituitary signal that drives the thyroid. Conventional range runs to about 4.5 mIU/L. Draw in the morning; pair with free thyroxine and thyroid antibodies if elevated | | Estradiol (early follicular) | 25–75 pg/mL | Frames the estrogen-to-progesterone balance that premenstrual symptoms track | Draw on days 2–4 of the cycle. Interpret alongside follicle-stimulating hormone, since both are needed to place someone within the menopausal transition | | Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) | LH-to-FSH ratio below 2:1, with FSH below 10 mIU/mL early in the cycle | Distinguishes polycystic ovary syndrome and the menopausal transition, both of which change the expected response | Draw on days 2–4. A ratio above 2:1 supports polycystic ovary syndrome, where response to chaste tree is inconsistent | | Alanine aminotransferase (ALT) | Below 25 U/L in women | Provides a reference value; no liver toxicity is known, but botanical product purity varies | ALT is a liver enzyme released when liver cells are stressed. Conventional upper limits reach roughly 33 U/L. Worth repeating only if fatigue, yellowing of the skin or abdominal pain appears | | Ferritin (the stored form of iron) | 50–100 ng/mL | Heavy or irregular bleeding, a common reason for starting the herb, depletes iron stores | No target specific to chaste tree exists; track change from the individual's own baseline. Ferritin rises with inflammation, so pair with C-reactive protein | Qualitative markers worth tracking alongside the laboratory values: * **Premenstrual symptom diary:** Rate irritability, mood, anger, headache, bloating and breast fullness daily. A 50% fall in the total score across three cycles is the responder definition used in the pivotal trials. * **Breast comfort:** Record the number of days per cycle with breast tenderness and its peak intensity on a 0–10 scale, since this is the most mechanistically responsive symptom. * **Cycle regularity:** Log cycle length and bleeding days. A stable 26–32 day cycle with a luteal phase of at least eleven days is the practical target. * **Sleep quality:** Note whether premenstrual sleep disruption resolves, since disrupted sleep is both a symptom and a driver of the nocturnal prolactin surge. * **Energy and cognitive clarity:** Note whether the premenstrual dip in energy and concentration narrows, which is often the change people value most. * **Skin:** Track whether cyclical acne improves or worsens, because the direction is individual and cannot be predicted in advance. ## Emerging Research * **Primary dysmenorrhea, phase 3:** A 335-participant randomized trial of BNO 1095 in primary dysmenorrhea (painful periods without underlying pelvic disease) has completed, with response defined as at least a three-point fall in peak pelvic pain without extra painkillers ([NCT06211049](https://clinicaltrials.gov/study/NCT06211049)). Manufacturer-sponsored; results unpublished. * **Mammographic breast density:** A 150-participant trial of the chaste tree product Cyclodynon in women aged 40–52 uses mammographic density as its primary endpoint, testing whether the herb moves a recognized breast-cancer risk marker ([NCT04498013](https://clinicaltrials.gov/study/NCT04498013)). Status last reported as unknown. * **Benign breast disease:** A completed 150-participant trial evaluated phytomedicine monotherapy in fibrocystic breast disease using pain scores and ultrasound ([NCT05717894](https://clinicaltrials.gov/study/NCT05717894)). Run independently of the two European manufacturers, which makes it a useful check on sponsor-linked findings. * **Metabolic effects in polycystic ovary syndrome:** A 60-participant randomized trial reported improved antioxidant capacity, insulin resistance and hirsutism scores ([Hatami et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41428718/)). If replicated, this extends the herb beyond cycle symptoms into metabolic territory relevant to long-term health. * **Receptor pharmacology:** Microfractionation of Ze 440 identified viteagnusin I and the triterpene 3-epi-maslinic acid as dopamine D2 activators, revising the assumption that clerodane diterpenes alone carry the activity ([Reinhardt et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39519010/)). Enrichment for potency becomes feasible. * **Evidence that could weaken the case:** The largest pooled analysis found funnel-plot asymmetry and a failing Egger test, indicating unpublished negative trials ([Verkaik et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28237870/)). A well-powered randomized trial of a chaste tree combination in menopause found no benefit at all ([van Die et al., 2009](https://pubmed.ncbi.nlm.nih.gov/18791483/)). * **The unmeasured long term:** No trial has run beyond roughly six months and no cohort has followed continuous users for years. Whether sustained prolactin suppression carries bone, metabolic or breast consequences across decades is unstudied rather than reassuring. ## Conclusion Chaste tree is a Mediterranean fruit extract that works by nudging the brain's hormone-control center to release less of the milk-producing hormone prolactin. For adults who track and manage a menstrual cycle as part of a long-term health strategy, the evidence is strongest for two things: the cluster of physical and mood symptoms that arrive before a period, and breast pain that recurs at the same point each month. Several trials and two separate pooled analyses point the same way, and the effect on breast pain holds up against prescription alternatives. Effects on cycle length and on the hormone pattern of the cycle's second half rest on thinner ground, and the claims around fertility, menopause and metabolic health remain early. The safety picture is unusually reassuring for a hormonally active plant. Reported problems are mild and reversible — stomach upset, headache, shifts in bleeding pattern, skin reactions — and none has escalated across decades of use. The real constraints are situational rather than toxic: pregnancy, breastfeeding, hormone-sensitive cancers, and any active fertility treatment. The evidence base carries a caveat that deserves equal weight. Most trials were funded or conducted by the two European companies that make the standardized extracts, the expert bodies endorsing the herb draw on practitioners with a stake in herbal medicine, and the largest pooled analysis found clear signs that negative trials went unpublished. The signal looks real; its size is probably overstated. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**